ESR1 and breast carcinoma: Moreover, a recent report describes the ability of cardiac glycosides Ouabain and Digoxin to degrade ERα, potentially via activation of the proteasomal system, with subsequent inhibition of estrogen signaling, cell cycle blockade and apoptosis of primary and metastatic breast cancer cells [106].